title: [Effective Prevention of Hand-Foot Syndrome by the Consumption of Dried Bonito Broth].
abstract: To examine whether the consumption of dried bonito both is effective for the prevention of hand-foot syndrome(HFS), concentrated bonito broth was administered to 10 patients with HCC who were treated with sorafenib. Among the 10 patients, seven showed an increase in peripheral blood flow, as observed on Doppler ultrasonography. Only one patient showed Grade 1 HFS on day 14 after the initiation of sorafenib (10%); this incidence rate of HFS was significantly lower than that obtained in our previous studies and reported data. These results suggest that consumption of dried bonito broth contributes to the prevention of HFS by maintaining peripheral blood flow.
authors.affiliation: Division of Gastroenterology, and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University.
authors.forename: Kenya
authors.initials: K
authors.lastname: Kamimura
authors.forename: Yoko
authors.initials: Y
authors.lastname: Shinagawa
authors.forename: Kohei
authors.initials: K
authors.lastname: Ogawa
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Abe
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yokoo
authors.forename: Hiroteru
authors.initials: H
authors.lastname: Kamimura
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Kawai
authors.forename: Takeshi
authors.initials: T
authors.lastname: Suda
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamagiwa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Baba
authors.forename: Shuji
authors.initials: S
authors.lastname: Terai
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005396:Fish Products; D060831:Hand-Foot Syndrome / Q000517:prevention & control*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib